SGCB

Across TCGA pan-cancer cohorts, SGCB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SGCB data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SGCB mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SGCB expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where SGCB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.361	0.707	.001	27	view →
LSCC	DFS	Quartile	II,III,IV	0.425	0.823	.016	19	view →
CCRCC	OS	Quartile	II,III,IV	0.331	1.000	.006	5	view →
HNSC	OS	Tertile	II,III,IV	0.925	1.000	.013	4	view →
GBM	OS	Quartile	All	0.579	0.378	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SGCB–PDAC (OS)

Open the PDAC breakdown →